This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Veracyte Q3 Earnings Beat Estimates, 2024 Guidance Raised
by Zacks Equity Research
VCYT registers robust growth from its market-leading Decipher Prostate and Afirma tests.
Veracyte (VCYT) Tops Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Veracyte (VCYT) delivered earnings and revenue surprises of 850% and 5.81%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
HSIC Q3 Earnings Top, Margins Down, Stock Gains in Premarket
by Zacks Equity Research
Henry Schein's third-quarter results reflect an improvement in sales trends in Technology and Value-Added Services business.
ILMN Q3 Earnings Top, '24 Sales View Down, Stock Dips in Aftermarket
by Zacks Equity Research
Illumina's third- quarter revenues from the consumables business show robust growth, offset by the declining instruments business.
Hologic (HOLX) Q4 Earnings Miss Estimates
by Zacks Equity Research
Hologic (HOLX) delivered earnings and revenue surprises of -0.98% and 0.88%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
IDXX Q3 Earnings Top, '24 Sales View Down, Stock Dips in Premarket
by Zacks Equity Research
IDXX's Q3 revenues benefit from strong growth in its CAG and Water segments.
BIO Q3 Earnings and Revenues Surpass Estimates, Stock Up Aftermarket
by Zacks Equity Research
Bio-Rad witnesses growth across the Clinical Diagnostics segment in the third quarter, primarily driven by an increased demand for quality control and immunology products.
CHE Misses on Q3 Earnings, Lowers '24 EPS View, Stock Up
by Zacks Equity Research
Chemed's VITAS segment reports impressive revenue growth and margin expansion for the third quarter of 2024.
Paragon 28, Inc. (FNA) Stock Jumps 7.2%: Will It Continue to Soar?
by Zacks Equity Research
Paragon 28, Inc. (FNA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
ICLR Misses on Q3 Earnings, Lowers 2024 Guidance, Stock Falls
by Zacks Equity Research
ICON's third-quarter 2024 earnings lag estimates due to its large customers undergoing significant development model shifts with resulting cost pressures and the biotech market's slower recovery.
EW Q3 Earnings Match Estimates, Revenues Miss, Stock Falls
by Zacks Equity Research
Edwards Lifesciences reports strong contributions from all of the product groups - TAVR, TTMT and surgical structural heart - in the third quarter of 2024.
LH Beats on Q3 Earnings, Raises Revenue Guidance Midpoint, Stock Gains
by Zacks Equity Research
Labcorp beats on earnings and revenues in the third quarter, entering the fourth half of 2024 with robust momentum.
DGX Stock Rises on Q3 Earnings and Revenue Beat, 2024 Sales View Up
by Zacks Equity Research
Quest Diagnostics' third-quarter 2024 performance reflects impressive DIS business growth and the benefits of new acquisitions.
WBA Stock Up on Q4 Earnings & Revenues Beat, Unveils Strategic Action
by Zacks Equity Research
Walgreens reports better-than-expected earnings and revenues in the fourth quarter of fiscal 2024.
How to Find Strong Buy Medical Stocks Using the Zacks Rank
by Zacks Equity Research
Finding strong, market-beating stocks with a positive earnings outlook becomes easier with the Zacks Rank.
EXAS Gains FDA Nod for Cologuard Plus, Progresses With CRC Screening
by Zacks Equity Research
Per the findings of the pivotal BLUE-C study, the Cologuard Plus test of Exact Sciences stands out for its high sensitivity at a specificity of 94%.
Here's How Much a $1000 Investment in Veracyte Made 10 Years Ago Would Be Worth Today
by Zacks Equity Research
Holding on to popular or trending stocks for the long-term can make your portfolio a winner.
3 MedTech Stocks to Buy as Monetary Policy Eases
by Urmimala Biswas
Here, we pick three MedTech stocks, VCYT, BSX and PAHC, which are anticipated to gain strongly in 2024 from the loosening of monetary policy.
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Looking for Medical Stocks? The Zacks Rank Can Help You Find Winners
by Zacks Equity Research
The Zacks Rank offers investors a way to easily find top-rated stocks and build a winning investment portfolio. Here's why you should take advantage.
Here's How Much You'd Have If You Invested $1000 in Veracyte a Decade Ago
by Zacks Equity Research
Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.
Zacks Industry Outlook Intuitive Surgical, Masimo and Veracyte
by Zacks Equity Research
Intuitive Surgical, Masimo and Veracyte have been highlighted in this Industry Outlook article
3 Medical Instruments Industry Stocks to Buy on genAI and M&A Boost
by Urmimala Biswas
ISRG, MASI and VCYT from the Zacks Medical Instruments industry are worth buying based on genAI adoption, strategic developments and strong fundamentals. Yet, geopolitical complications and wage and supply issues mar the prospects.
Here's Why VCYT Stock Could be a Great Addition to Your Portfolio Now
by Zacks Equity Research
Veracyte looks poised to deliver robust performance owing to its progress with key drivers and the strength in its diagnostics tests.
Veracyte (VCYT) Up 9.2% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Veracyte (VCYT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.